<DOC>
	<DOCNO>NCT00375817</DOCNO>
	<brief_summary>To assess efficacy safety MyoCell therapy myocardial function congestive heart failure patient , post-myocardial infarction</brief_summary>
	<brief_title>Safety Effects Implanted ( Autologous ) Skeletal Myoblasts ( MyoCell ) Using Injection Catheter = SEISMIC Trial</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>define region myocardial dysfunction relate previous MI ( recent MI least 90 day prior muscle biopsy involve anterior , lateral , posterior inferior wall , assess presence Qwave ECG &amp; large area akinesia leave ventricle , confirm either leave ventricular angiography echocardiography NYHA class II III optimal medical drug therapy least 2 month prior study entry ; define current ACC/AHA guideline Evaluation &amp; Management chronic heart failure adult &gt; =18 &lt; =75 year old need feasibility revascularization r/o coronary noninvasive stress test within 30 day screen , assess use Dobutamine Stress Echocardiography able undergo surgical biopsy skeletal muscle &amp; successful culture harvest myoblasts well demarcated transmural myocardial scar ( echocardiography ) Must minimum myocardial wall thickness 5mm must fit w/ ICD place duration study least 6 month prior muscle biopsy leave ventricular EF screen &gt; =20 % , &lt; =45 % ( MUGA ) willing &amp; able give write informed consent female childbearing potential , serum urine pregnancy test must negative w/in 2 week study treatment MI w/in 90 day muscle biopsy NYHA class I IV CABG w/in 6 month ( 180 day ) prior schedule MyoCell implantation PCI w/in 3 month ( 90 day ) prior schedule MyoCell implantation aortic valve replacement heart failure secondary valvular disease leave ventricular mural thrombus know sensitivity gentamicin sulfate and/or amphotericinB previous experimental angiogenic therapy and/or myocardial laser therapy previous severe adverse reaction nonionic radiocontrast agent exposure investigational drug procedure w/in 1 month prior study entry enrol concurrent study may confound result study serum creatinine &gt; 2.5 mg/dL end stage renal disease active infectious disease and/or know test positive HIV , HTLV , HBV , HCV , CMV ( IgM &gt; IgG ) and/or syphilis . If panel include antibody HBVcAg HBVsAg , expert consult patient eligibility base patient 's infectious status female pregnant nurse childbearing potential unwilling maintain contraceptive therapy duration study illness might affect patient 's survival study follow period illness , investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result patient chronic immunosuppressive transplant therapy ICDs implant less 6 month prior cellular implantation procedure . ICDs reprogrammed course treatment stable le 3 month . Patients fit w/a BiV pacer exclude . patient , opinion investigator , suitable participate , follow review catheter information appendix IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>